key: cord-0832176-yofjfn2i
authors: Levy, Joshua M.; Frediani, Jennifer K.; Tyburski, Erika A.; Wood, Anna; Figueroa, Janet; Kempker, Russell R.; Rebolledo, Paulina A.; Gonzalez, Mark D.; Sullivan, Julie; Vos, Miriam B.; O’Neal, Jared; Martin, Greg S.; Lam, Wilbur A.; Waggoner, Jesse J.
title: Impact of repeated nasal sampling on detection and quantification of SARS-CoV-2
date: 2021-07-21
journal: Sci Rep
DOI: 10.1038/s41598-021-94547-0
sha: 423bfe64fd89e62b6ec8424ca6855d3f417c84ac
doc_id: 832176
cord_uid: yofjfn2i

The impact of repeated sample collection on COVID-19 test performance is unknown. The FDA and CDC currently recommend the primary collection of diagnostic samples to minimize the perceived risk of false-negative findings. We therefore evaluated the association between repeated sample collection and test performance among 325 symptomatic patients undergoing COVID-19 testing in Atlanta, GA. High concordance was found between consecutively collected mid-turbinate samples with both molecular (n = 74, 100% concordance) and antigen-based (n = 147, 97% concordance, kappa = 0.95, CI = 0.88–1.00) diagnostic assays. Repeated sample collection does not decrease COVID-19 test performance, demonstrating that multiple samples can be collected for assay validation and clinical diagnosis.

Both the FDA and CDC have expressed concern that the sensitivity of SARS-CoV-2 detection may decline in sequentially collected samples. Previous device evaluations employed a number of study designs to address this issue, including the use of different nares 3 , distinct anatomical sites 4,5 , or alternating the order of sample collection 6 . However, in clinical practice, such measures are not possible and may introduce different biases, such as diagnostic yield between different nares or specimen types 7 . The current study demonstrates high concordance between sequential MT samples collected during a single clinical encounter, including complete concordance of results among 74 paired samples tested by rRT-PCR and 97% concordance among paired samples tested for SARS-CoV-2 antigen. These data demonstrate there is ample SARS-CoV-2 virus across a range of viral loads (based on Ct values) to allow for repeated MT sampling if required for multiple tests. In addition, these data support the use of MT sampling as a less invasive collection method for point-of-care and potentially at home testing, with 88.8% concordance (exact CI = 0.82-0.93) between MT antigen test and NP rRT-PCR results. The current study focused on MT samples, which are being increasingly used for SARS-CoV-2 diagnostic testing 3 . These results cannot necessarily be generalized to the collection of other nasal or oral specimens. Additionally, we did not vary the order of the nasal sampling with SOC NP sampling. In pediatric patients, NP samples were always last and in adults they were always first. Despite these limitations, this study provides proof that SARS-CoV-2 diagnostic test performance is maintained among multiple MT samples when taken at the same encounter. These data have implications for clinical testing algorithms and the design of future device evaluation studies.

Clinical samples. Paired, sequential MT swabs were obtained from 325 participants from COVID-19 testing centers utilized by the Atlanta Center for Microsystems Engineered Point-of-Care Technologies (ACME-POCT) network and affiliated with Emory University, Grady Memorial Hospital and Children's Healthcare of Atlanta. Inclusion criteria were symptomatic respiratory illness for ≤ 7 days and a documented SARS-CoV-2 molecular test obtained within 24 h of study enrollment. SOC molecular tests differed by site and included the Roche Cobas 6800, Abbott Alinity, and Panther Fusion. NP swabs obtained for SOC testing were collected prior to MT swabs Figure 1) . MT swabs for rRT-PCR testing were collected using flocked tapered swabs (Copan FLOQSwab, Ref # 520CS01) 8 . Swabs were placed in 1 mL of saline in a sterile tube. Samples were stored at 4 °C for up to 72 h or − 80 °C if longer delays were expected. Samples were extracted from 500 µL of saline on an eMAG instrument (bioMeriéux) and eluted in 50 µL of buffer. Eluates were tested in an internally controlled, duplex rRT-PCR for the SARS-CoV-2 N2 target and RNase P. Oligonucleotide concentrations, master mix preparation, and cycling conditions were maintained from a previously published, triplex assay that included these two targets 9 . Paired MT swabs were tested side-by-side on a single run. Sample collection was the same for antigen tests and were completed using the Abbott BinaxNOW™ COVID-19 Ag Card Home Test (Abbott Laboratories, Abbott Park, IL). Results were recorded for both completed tests.

Statistical analysis. Statistical analyses were performed using SAS 9.4 (Cary, NC). Agreement between the first (MT1) and second MT (MT2) antigen results was assessed using Cohen's Kappa coefficient with exact 95% confidence intervals. McNemar's test evaluated overall differences in MT1 vs. MT2 antigen results. Paired t-tests were used for MT1 vs. MT2 Ct comparisons and Wilcoxon signed-rank tests were used for overall adult vs. pediatric Ct comparisons.

Challenges and controversies to testing for Covid-19

Sars-Cov-2 viral load in upper respiratory specimens of infected patients

Head-to-head comparison of Sars-Cov-2 antigen-detecting rapid test with self-collected anterior nasal swab versus professional-collected nasopharyngeal swab

Evaluation of Abbott Binaxnow rapid antigen test for Sars-Cov-2 infection at two community-based testing sites-Pima County

Open development and clinical validation of multiple 3d-printed nasopharyngeal collection swabs: Rapid resolution of a critical Covid-19 testing bottleneck

Covid-19) antigen card test relative to the severe acute respiratory coronavirus virus 2 (Sars-Cov-2) real-time reverse transcriptase polymerase chain reaction (Rrt-Pcr) assay among symptomatic and asymptomatic healthcare employees

Detection of Sars-Cov-2 in different types of clinical specimens

Interim Guidelines for Collecting and Handling of Clinical Specimensfor COVID-19 Testing

Triplex real-time Rt-Pcr for severe acute respiratory syndrome coronavirus 2

Trial oversight, coordination, analysis, drafting of manuscript. E.A.T.-Coordination, drafting of manuscript. A.W.-Data analysis and interpretation, drafting of manuscript. J.F.-Data analysis and interpretation, drafting of manuscript. R.R.K.-Patient enrollment, oversight and manuscript review

Trial oversight, coordination, data analysis, manuscript review. W.A.L.-Trial oversight, coordination, data analysis, manuscript review

The authors declare no competing interests.